G1 Therapeutics: CRC Topline is a high risk-reward binary event
Nico El Nino G1 Therapeutics (NASDAQ: GTHX) sells Cosela or trilaciclib, a myelosuppressant drug that was approved in February 2021 as an adjunct to chemotherapy in later stage small cell lung cancer (ES-SCLC, extended stage small cell lung cancer) patients. Unlike other myeloprotective agents that are lineage-specific, trilaciclib protects against chemotherapy patients of all three […]
Continue Reading